LCM
ALXN

Laurion Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Laurion Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-160,000
Closed -$22.4M – 1960
2017
Q3 		$22.4M Buy
+160,000
New +$21.7M 0.1% 171

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Laurion Capital Management's ALXN Position: Q2 2021 in Review

Laurion Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 11,200 shares — an estimated $1.71M sold.

Laurion Capital Management first reported a position in ALXN in Q2 2015 and held it in 8 quarters. The position peaked at $10.8M in Q1 2017. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Laurion Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 11,200 Alexion Pharmaceuticals shares in Q2 2021, an estimated $1.71M.
  • Laurion Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 8 quarters.
  • Laurion Capital Management's Alexion Pharmaceuticals position peaked at $10.8M in Q1 2017.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.